Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of HLX43 alone or with serplulimab in advanced triple-negative breast cancer
CTR20260963Phase 2Active
- Sponsor
- HyBioPharma
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HLX43, serplulimab in triple-negative breast cancer (TNBC), sponsored by HyBioPharma. Started Apr 2026; status: active.
02
Drugs
HLX43serplulimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20260963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260963.